A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients

Chris J. Buckland-Wright, E. A. Messent, Clifton Bingham, R. J. Ward, C. Tonkin

Research output: Contribution to journalArticle

Abstract

Objectives. To determine whether risedronate (RIS) slows down trabecular bone loss in the medial compartment of the proximal tibia, a characteristic of patients with progressive knee osteoarthritis (OA). Methods. Initially, 100 patients were randomly selected from each treatment group (each N∼300) comprising placebo and RIS 5 mg/day, 15 mg/day and 50 mg/week from a double blind, multi-centre, placebo-controlled, 2 yr investigation of OA knee patients in North America. Using fluoroscopic semi-flexed standard radiography, baseline and exit knee radiographs were digitized by laser scanner. Following computerized measurement of minimum medial compartment joint space width, each group was subdivided into joint space narrowing (JSN) non-progressor or JSN-progressor (JSN ≥0.6 mm measured at any point post-baseline). Computerized method of fractal signature analysis (FSA) quantified longitudinal changes separately in horizontal and vertical trabeculae in region of interest (three-fourth width of tibial compartment × 6 mm height) in the medial compartment. Following the initial study, all JSN-progressor knees within the entire patient cohort (N = 1232) were similarly analysed. Results. OA knees in JSN non-progressor group had a slight decrease in FSA for vertical and horizontal trabeculae and showed no drug effect. In JSN-progressor knees, bone loss was greater in both placebo and RIS 5 mg/day groups compared with those in RIS 15 mg/day group in which trabeculae were retained, and in the RIS 50 mg/week group in which the vertical trabecular number increased significantly (P <0.05). Conclusion. This preliminary study showed that patients with marked cartilage loss (JSN≥0.6 mm) receiving RIS 15 mg/day retained vertical trabecular structure, and those receiving RIS 50 mg/week increased vertical trabecular number, thereby preserving the structural integrity of subchondral bone in knee OA.

Original languageEnglish (US)
Pages (from-to)257-264
Number of pages8
JournalRheumatology
Volume46
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Diphosphonates
Longitudinal Studies
Knee
Knee Osteoarthritis
Joints
Bone and Bones
Fractals
Placebos
Knee Joint
North America
Risedronate Sodium
Tibia
Radiography
Cartilage
Lasers
Pharmaceutical Preparations

Keywords

  • Bisphosphonates
  • Bone structure
  • Knee
  • Osteoarthritis
  • Radiography
  • Risedronate
  • Trabeculae

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Cite this

A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. / Buckland-Wright, Chris J.; Messent, E. A.; Bingham, Clifton; Ward, R. J.; Tonkin, C.

In: Rheumatology, Vol. 46, No. 2, 02.2007, p. 257-264.

Research output: Contribution to journalArticle

@article{6d826456df5f4fb394c05435e033bcfa,
title = "A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients",
abstract = "Objectives. To determine whether risedronate (RIS) slows down trabecular bone loss in the medial compartment of the proximal tibia, a characteristic of patients with progressive knee osteoarthritis (OA). Methods. Initially, 100 patients were randomly selected from each treatment group (each N∼300) comprising placebo and RIS 5 mg/day, 15 mg/day and 50 mg/week from a double blind, multi-centre, placebo-controlled, 2 yr investigation of OA knee patients in North America. Using fluoroscopic semi-flexed standard radiography, baseline and exit knee radiographs were digitized by laser scanner. Following computerized measurement of minimum medial compartment joint space width, each group was subdivided into joint space narrowing (JSN) non-progressor or JSN-progressor (JSN ≥0.6 mm measured at any point post-baseline). Computerized method of fractal signature analysis (FSA) quantified longitudinal changes separately in horizontal and vertical trabeculae in region of interest (three-fourth width of tibial compartment × 6 mm height) in the medial compartment. Following the initial study, all JSN-progressor knees within the entire patient cohort (N = 1232) were similarly analysed. Results. OA knees in JSN non-progressor group had a slight decrease in FSA for vertical and horizontal trabeculae and showed no drug effect. In JSN-progressor knees, bone loss was greater in both placebo and RIS 5 mg/day groups compared with those in RIS 15 mg/day group in which trabeculae were retained, and in the RIS 50 mg/week group in which the vertical trabecular number increased significantly (P <0.05). Conclusion. This preliminary study showed that patients with marked cartilage loss (JSN≥0.6 mm) receiving RIS 15 mg/day retained vertical trabecular structure, and those receiving RIS 50 mg/week increased vertical trabecular number, thereby preserving the structural integrity of subchondral bone in knee OA.",
keywords = "Bisphosphonates, Bone structure, Knee, Osteoarthritis, Radiography, Risedronate, Trabeculae",
author = "Buckland-Wright, {Chris J.} and Messent, {E. A.} and Clifton Bingham and Ward, {R. J.} and C. Tonkin",
year = "2007",
month = "2",
doi = "10.1093/rheumatology/kel213",
language = "English (US)",
volume = "46",
pages = "257--264",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients

AU - Buckland-Wright, Chris J.

AU - Messent, E. A.

AU - Bingham, Clifton

AU - Ward, R. J.

AU - Tonkin, C.

PY - 2007/2

Y1 - 2007/2

N2 - Objectives. To determine whether risedronate (RIS) slows down trabecular bone loss in the medial compartment of the proximal tibia, a characteristic of patients with progressive knee osteoarthritis (OA). Methods. Initially, 100 patients were randomly selected from each treatment group (each N∼300) comprising placebo and RIS 5 mg/day, 15 mg/day and 50 mg/week from a double blind, multi-centre, placebo-controlled, 2 yr investigation of OA knee patients in North America. Using fluoroscopic semi-flexed standard radiography, baseline and exit knee radiographs were digitized by laser scanner. Following computerized measurement of minimum medial compartment joint space width, each group was subdivided into joint space narrowing (JSN) non-progressor or JSN-progressor (JSN ≥0.6 mm measured at any point post-baseline). Computerized method of fractal signature analysis (FSA) quantified longitudinal changes separately in horizontal and vertical trabeculae in region of interest (three-fourth width of tibial compartment × 6 mm height) in the medial compartment. Following the initial study, all JSN-progressor knees within the entire patient cohort (N = 1232) were similarly analysed. Results. OA knees in JSN non-progressor group had a slight decrease in FSA for vertical and horizontal trabeculae and showed no drug effect. In JSN-progressor knees, bone loss was greater in both placebo and RIS 5 mg/day groups compared with those in RIS 15 mg/day group in which trabeculae were retained, and in the RIS 50 mg/week group in which the vertical trabecular number increased significantly (P <0.05). Conclusion. This preliminary study showed that patients with marked cartilage loss (JSN≥0.6 mm) receiving RIS 15 mg/day retained vertical trabecular structure, and those receiving RIS 50 mg/week increased vertical trabecular number, thereby preserving the structural integrity of subchondral bone in knee OA.

AB - Objectives. To determine whether risedronate (RIS) slows down trabecular bone loss in the medial compartment of the proximal tibia, a characteristic of patients with progressive knee osteoarthritis (OA). Methods. Initially, 100 patients were randomly selected from each treatment group (each N∼300) comprising placebo and RIS 5 mg/day, 15 mg/day and 50 mg/week from a double blind, multi-centre, placebo-controlled, 2 yr investigation of OA knee patients in North America. Using fluoroscopic semi-flexed standard radiography, baseline and exit knee radiographs were digitized by laser scanner. Following computerized measurement of minimum medial compartment joint space width, each group was subdivided into joint space narrowing (JSN) non-progressor or JSN-progressor (JSN ≥0.6 mm measured at any point post-baseline). Computerized method of fractal signature analysis (FSA) quantified longitudinal changes separately in horizontal and vertical trabeculae in region of interest (three-fourth width of tibial compartment × 6 mm height) in the medial compartment. Following the initial study, all JSN-progressor knees within the entire patient cohort (N = 1232) were similarly analysed. Results. OA knees in JSN non-progressor group had a slight decrease in FSA for vertical and horizontal trabeculae and showed no drug effect. In JSN-progressor knees, bone loss was greater in both placebo and RIS 5 mg/day groups compared with those in RIS 15 mg/day group in which trabeculae were retained, and in the RIS 50 mg/week group in which the vertical trabecular number increased significantly (P <0.05). Conclusion. This preliminary study showed that patients with marked cartilage loss (JSN≥0.6 mm) receiving RIS 15 mg/day retained vertical trabecular structure, and those receiving RIS 50 mg/week increased vertical trabecular number, thereby preserving the structural integrity of subchondral bone in knee OA.

KW - Bisphosphonates

KW - Bone structure

KW - Knee

KW - Osteoarthritis

KW - Radiography

KW - Risedronate

KW - Trabeculae

UR - http://www.scopus.com/inward/record.url?scp=33846655848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846655848&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kel213

DO - 10.1093/rheumatology/kel213

M3 - Article

C2 - 16837470

AN - SCOPUS:33846655848

VL - 46

SP - 257

EP - 264

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 2

ER -